Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Adaptive, Double-blinded, Placebo Controlled, Randomized, Multi-center Trial to Evaluate the Efficacy, Safety and Tolerability of Intracoronary Infusion of AB-1002 in Adult Subjects With New York Heart Association (NYHA) Class III Heart Failure and Non-ischemic Cardiomyopathy

NCT05598333 is registered in ClinicalTrials.gov with AskBio Inc as lead sponsor.

NCT NCT05598333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05598333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Adaptive, Double-blinded, Placebo Controlled, Randomized, Multi-center Trial to Evaluate the Efficacy, Safety and Tolerability of Intracoronary Infusion of AB-1002 in Adult Subjects With New York Heart Association (NYHA) Class III Heart Failure and Non-ischemic Cardiomyopathy
Lead sponsor
AskBio Inc
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 20, 2023
Completion date
December 31, 2030
Enrollment
150 (estimated)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

congestive heart failure